What is a stock summary page? Click here for an overview.
Business Description
BioRestorative Therapies Inc
NAICS : 541714
SIC : 8099
ISIN : US0906554086
Description
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 311.62 | |||||
| Equity-to-Asset | 0.69 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -14.67 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.3 | |||||
| 3-Year EBITDA Growth Rate | 35.6 | |||||
| 3-Year EPS without NRI Growth Rate | 37.4 | |||||
| 3-Year FCF Growth Rate | 17.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.61 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 180.96 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.95 | |||||
| 9-Day RSI | 68.21 | |||||
| 14-Day RSI | 59.19 | |||||
| 3-1 Month Momentum % | 3.9 | |||||
| 6-1 Month Momentum % | -13.03 | |||||
| 12-1 Month Momentum % | 15.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.95 | |||||
| Quick Ratio | 2.95 | |||||
| Cash Ratio | 2.86 | |||||
| Days Sales Outstanding | 55.19 | |||||
| Days Payable | 3690.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -87.3 | |||||
| Shareholder Yield % | 1.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.37 | |||||
| Operating Margin % | -3205.84 | |||||
| Net Margin % | -2558.89 | |||||
| FCF Margin % | -2000.27 | |||||
| ROE % | -82.99 | |||||
| ROA % | -64.27 | |||||
| ROIC % | -323.61 | |||||
| 3-Year ROIIC % | -770.21 | |||||
| ROC (Joel Greenblatt) % | -2637.71 | |||||
| ROCE % | -103.89 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 39.87 | |||||
| PB Ratio | 1.37 | |||||
| Price-to-Tangible-Book | 1.46 | |||||
| EV-to-EBIT | 0.06 | |||||
| EV-to-EBITDA | 0.06 | |||||
| EV-to-Revenue | -1.99 | |||||
| EV-to-Forward-Revenue | 0.07 | |||||
| EV-to-FCF | 0.16 | |||||
| Price-to-GF-Value | 0.56 | |||||
| Price-to-Median-PS-Value | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 1.53 | |||||
| Price-to-Net-Cash | 1.6 | |||||
| Earnings Yield (Greenblatt) % | 1666.67 | |||||
| FCF Yield % | -55.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioRestorative Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.377 | ||
| EPS (TTM) ($) | -1.43 | ||
| Beta | 1.01 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 106.46 | ||
| 14-Day RSI | 59.19 | ||
| 14-Day ATR ($) | 0.174812 | ||
| 20-Day SMA ($) | 1.65 | ||
| 12-1 Month Momentum % | 15.11 | ||
| 52-Week Range ($) | 1.03 - 2.55 | ||
| Shares Outstanding (Mil) | 6.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioRestorative Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioRestorative Therapies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioRestorative Therapies Inc Frequently Asked Questions
What is BioRestorative Therapies Inc(BRTX)'s stock price today?
The current price of BRTX is $1.97. The 52 week high of BRTX is $2.55 and 52 week low is $1.03.
When is next earnings date of BioRestorative Therapies Inc(BRTX)?
The next earnings date of BioRestorative Therapies Inc(BRTX) is .
Does BioRestorative Therapies Inc(BRTX) pay dividends? If so, how much?
BioRestorative Therapies Inc(BRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers